EDGAR·FLOW

Summit Therapeutics Inc. — Form 8-K

Filed September 28, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
AstraZeneca Holdings B.V. is investing $2.0 billion in Summit Therapeutics through purchase of approximately 108,955 shares of Class A Convertible Preferred Stock convertible into common stock at a 1:1,000 ratio, implying a per-share price of $18.36 (VWAP plus 10%). The transaction includes a clinical collaboration agreement to evaluate ivonescimab combined with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers, plus a non-binding MOU for future trials combining ivonescimab with AstraZeneca's ADC portfolio. Closing expected by end of week.
Why this rating

Large strategic capital infusion ($2B ≈ 80% of company market cap) validates pipeline, funds R&D, provides non-dilutive near-term benefit to existing shareholders; creates pharma partnership de-risking clinical development.

Tradability signal
NO TRADE

No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.38% over 4 hrs, n=124). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$15.48
+10 min · unknown
$16.65 ▲ 7.55%
+30 min · unknown
$16.56 ▲ 6.98%
+1 hr · unknown
$16.44 ▲ 6.20%
+4 hrs · unknown
$16.27 ▲ 5.10%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SMMT · stock on Yahoo Finance ↗

See more from September 28, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.